Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor

Open access

Abstract

High Resolution Image Download MS PowerPoint Slide KRAS G12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS G12C, selective inhibition of KRAS G12D presents a significant challenge due to the requirement of inhibitors to bind KRAS G12D with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS G12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS G12D mutant xenograft mouse tumor model.

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.1c01688

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

21 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. Bos J. L., 1989, Cancer Res., 49, 4682

Cited by

See all 787

Metadata

Authors
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., Hallin, J., Laguer, J., Lawson, J. D., Medwid, J., Newhouse, B., Nguyen, P., O’Leary, J. M., Olson, P., Pajk, S., Rahbaek, L., Rodriguez, M., Smith, C. R., Tang, T. P., Thomas, N. C., Vanderpool, D., Vigers, G. P., Christensen, J. G., & Marx, M. A.
Affiliations
  • Mirati Therapeutics (United States) (US)
  • Pfizer (United States) (US)
  • Mirati Therapeutics, San Diego, California 92121, United States
Corresponding author
  • Wang, Xiaolun
  • Marx, Matthew A.
Venue
Journal of Medicinal Chemistry
Published
2021-12-10
Volume
65
Issue
4
Pages
3123-3133
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4200173198
Cited by
769
References
31
Citations by year
2026: 176 · 2025: 204 · 2024: 188 · 2023: 135 · 2022: 66
FWCI
30.89
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1s10od021527-01)
  • National Institute of General Medical Sciences (P30GM133894, P30GM124165)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
MRTX1133, KRAS G12D, KRAS inhibitors, non-covalent inhibitors, oncogenic KRAS, structure-based drug design, xenograft tumor model, solid tumors, small molecule inhibitors
MeSH terms
Animals, Antineoplastic Agents, Humans, Models, Molecular, Mutation, Structure-Activity Relationship, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Mice, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01688
The paper
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., Hallin, J., Laguer, J., Lawson, J. D., Medwid, J., Newhouse, B., Nguyen, P., O’Leary, J. M., Olson, P., Pajk, S., . . . Marx, M. A. (2022). Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01688

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.